Accueil>>Biochemical Assay Reagents>>N-Succinimidyl-S-acetylthioacetate

N-Succinimidyl-S-acetylthioacetate (Synonyms: SATA)

Catalog No.GC39154

Le N-succinimidyl S-acétylthioacétate (SATA), un agent de modification des protéines, introduit des groupes thiol dans les molécules de protéines.

Products are for research use only. Not for human use. We do not sell to patients.

N-Succinimidyl-S-acetylthioacetate Chemical Structure

Cas No.: 76931-93-6

Taille Prix Stock Qté
10mM (in 1mL DMSO)
99,00 $US
En stock
50mg
90,00 $US
En stock
100mg
117,00 $US
En stock
200mg Please Inquire Please Inquire
500mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

N-Succinimidyl S-acetylthioacetate (SATA), a protein modification agent, introduces thiol-groups into protein molecules. N-Succinimidyl S-acetylthioacetate adds sulfhydryl groups to proteins and other amine-containing molecules in a protected form[1][2].

[1]. J.L.M.Heeremans, et al. Interference of ?-amino-caproic acid with [N-succinimidyl S-acetylthioacetate derived] thiol-introduction into glu-plasminogen. Volume 8, Supplement 2, 1994, Pages 138-141. [2]. Allen KJH, et al. Evaluation of N-Succinimidyl S-Acetylthioacetate Ligand for Radiolabeling of HumanizedAntibodies with 188Rhenium. Cancer Biother Radiopharm. 2018 Oct;33(8):349-355.

Avis

Review for N-Succinimidyl-S-acetylthioacetate

Average Rating: 5 ★★★★★ (Based on Reviews and 12 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for N-Succinimidyl-S-acetylthioacetate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.